Coherus Oncology, Inc. (CHRS)
1.05
+0.02
(+1.94%)
USD |
NASDAQ |
Oct 13, 13:46
Coherus Oncology Cash from Investing (Quarterly) : 29.63M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.63M |
| March 31, 2026 | 30.66M |
| December 31, 2025 | -2.838M |
| September 30, 2025 | -67.23M |
| June 30, 2025 | 462.64M |
| March 31, 2025 | -17.49M |
| December 31, 2024 | -0.542M |
| September 30, 2024 | 0.444M |
| June 30, 2024 | 27.66M |
| March 31, 2024 | 202.76M |
| December 31, 2023 | 35.20M |
| September 30, 2023 | 50.55M |
| June 30, 2023 | 41.36M |
| March 31, 2023 | 17.53M |
| December 31, 2022 | -129.90M |
| September 30, 2022 | -0.457M |
| June 30, 2022 | -0.88M |
| March 31, 2022 | -35.62M |
| December 31, 2021 | 107.49M |
| September 30, 2021 | 15.99M |
| June 30, 2021 | 23.58M |
| March 31, 2021 | -285.48M |
| December 31, 2020 | 210.06M |
| September 30, 2020 | 16.41M |
| June 30, 2020 | -239.25M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.616M |
| December 31, 2019 | -6.062M |
| September 30, 2019 | -0.289M |
| June 30, 2019 | 8.818M |
| March 31, 2019 | -15.20M |
| December 31, 2018 | 15.79M |
| September 30, 2018 | 12.81M |
| June 30, 2018 | -16.60M |
| March 31, 2018 | -13.18M |
| December 31, 2017 | 14.39M |
| September 30, 2017 | 28.71M |
| June 30, 2017 | 4.064M |
| March 31, 2017 | -51.58M |
| December 31, 2016 | -3.566M |
| September 30, 2016 | -0.50M |
| June 30, 2016 | -0.301M |
| March 31, 2016 | -2.148M |
| December 31, 2015 | -1.444M |
| September 30, 2015 | -3.184M |
| June 30, 2015 | -1.008M |
| March 31, 2015 | -1.313M |
| December 31, 2014 | -0.499M |
| September 30, 2014 | -0.807M |
| June 30, 2014 | -1.293M |
| March 31, 2014 | 2.074M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 14.00M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -62.09M |
| Cash from Financing (Quarterly) | 0.144M |
| Free Cash Flow | -186.03M |
| Free Cash Flow Per Share (Quarterly) | -0.4011 |
| Free Cash Flow to Equity (Quarterly) | -61.90M |
| Free Cash Flow to Firm (Quarterly) | -59.77M |
| Free Cash Flow Yield | -134.3% |